NEW YORK (GenomeWeb) – Tempus announced today that has partnered with the Vanderbilt-Ingram Cancer Center (VICC) to use cancer patient data to help personalize treatments.
Under the collaboration, Tempus will use its recently launched Tempus O informatics platform to collect and structure clinical data from VICC's electronic health records. The company will also perform next-generation sequencing and analysis for a subset of the center's patients in order to identify actionable gene alterations.
Additional terms of the deal were not disclosed.
"Collaborating with Tempus will allow the Vanderbilt-Ingram team to gain a deeper understanding of a patient's cancer and its genetic and molecular drivers, with a goal of improving patient outcomes," VICC Director Jennifer Pietenpol said in a statement.
The alliance with VICC is the latest in a series of similar deals Tempus has formed recently, including ones with the Cleveland Clinic, the University of California Davis Comprehensive Cancer Center, and University of Chicago Medicine.